Seeing Is Believing
Currently out of the existing stock ratings of Difei Yang, 176 are a BUY (88.44%), 21 are a HOLD (10.55%), 2 are a SELL (1.01%).
Analyst Difei Yang, currently employed carries an average stock price target met ratio of 48.53% that have a potential upside of 45.37% achieved within 277 days. Previously, Difei Yang worked at MIZUHO.
Difei Yang’s has documented 419 price targets and ratings displayed on 29 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 24-Jun-2022.
Analyst best performing recommendations are on RLYP (RELYPSA).
The best stock recommendation documented was for RLYP (RELYPSA) at 7/18/2016. The price target of $26 was fulfilled within 3 days with a profit of $5.75 (28.4%) receiving and performance score of 94.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$13
2 years 2 months 15 days ago
(29-Aug-2022)
1/5 (20%)
$4.7 (56.63%)
176
Hold
2 years 2 months 20 days ago
(24-Aug-2022)
0/1 (0%)
$6.53 (25.64%)
Hold
$20
2 years 2 months 20 days ago
(24-Aug-2022)
0/4 (0%)
$14.21 (245.42%)
Buy
$15.25
$27
2 years 2 months 21 days ago
(23-Aug-2022)
7/11 (63.64%)
$0.09 (0.59%)
149
Hold
$15.25
$30
2 years 2 months 21 days ago
(23-Aug-2022)
1/3 (33.33%)
$0.09 (0.59%)
48
What Year was the first public recommendation made by Difei Yang?